71,267 results match your criteria Lung Cancer Oat Cell Small Cell


Prognostic value of broad-spectrum keratin clones AE1/AE3 and CAM5.2 in small cell lung cancer patients undergoing pulmonary resection.

Acta Biochim Pol 2019 Feb 22. Epub 2019 Feb 22.

7Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland.

Introduction: Small cell lung carcinoma (SCLC) is an aggressive pulmonary neoplasm of neuroendocrine origin. Keratins form a large group of intermediate filaments, which are major structural proteins in epithelial cells and carcinomas. SCLC shows a wide spectrum of keratin expression, from very strong to completely negative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18388/abp.2018_2773DOI Listing
February 2019

Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.

Thorac Cancer 2019 Feb 21. Epub 2019 Feb 21.

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.

Background: The classification of large cell neuroendocrine carcinoma (LCNEC) has generated considerable debate and has been revised since its recognition as a separate entity. Although it shares clinical features with small cell lung carcinoma (SCLC) and was classified with SCLC in the 2015 World Health Organization classification system, numerous studies have revealed inferior treatment outcomes of LCNEC when it was treated as SCLC. Because the incidence of LCNEC is rare, its mutational landscape has not been comprehensively interrogated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13011DOI Listing
February 2019

Treatment-refractory paraneoplastic opsoclonus-myoclonus syndrome in a patient with small-cell carcinoma of the lung.

J Oncol Pharm Pract 2019 Feb 22:1078155219831366. Epub 2019 Feb 22.

1 Department of Internal Medicine, Medical Oncology Unit, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey.

Opsoclonus-myoclonus syndrome is a rare disease and traditionally described as "dancing eyes, dancing feet syndrome." It is characterized by opsoclonus (oscillations of the eyes in either horizontally or vertically) and myoclonus (spontaneous jerky movements of the limbs and trunk). There are numerous etiological factors defined such as paraneoplastic, para-infectious, toxic-metabolic, and idiopathic causes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219831366DOI Listing
February 2019

Potential Analysis and Preparation of Chitosan Oligosaccharides as Oral Nutritional Supplements of Cancer Adjuvant Therapy.

Int J Mol Sci 2019 Feb 20;20(4). Epub 2019 Feb 20.

College of Marine Life Sciences, Ocean University of China, Qingdao 266100, China.

Cancer is considered to have an adverse influence on health around the world. Chitosan, a linear polysaccharide that contains copolymers of β -1-4 linked d-glucosamine and -acetyl-d-glucosamine units, has been widely used in the field of biomedicine, owing to its nontoxicity, biocompatibility, biodegradability, and hemocompatibility. This study was aimed at preparing the chitosan oligosaccharides (COS) and examining its ability on suppressing lung cancer in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040920DOI Listing
February 2019

Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.

Abdom Radiol (NY) 2019 Feb 21. Epub 2019 Feb 21.

Department of Medical Oncology and Department of Medicine, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

Purpose: To investigate the frequency and imaging features of radiographically evident abdominal immune-related adverse events (irAEs) in patients with metastatic non-small-cell lung cancer (NSCLC) treated with PD-1 inhibitors.

Methods: This retrospective study included 137 patients with metastatic NSCLC treated with PD-1 inhibitor nivolumab monotherapy (75 women; median age: 65 years), who had a baseline CT and at least one follow-up abdomen CT during therapy. Baseline and all follow-up abdominal CTs performed for monitoring of nivolumab therapy were reviewed to identify the organ-specific abdominal irAEs including colitis/enteritis, hepatitis, biliary toxicity, pancreatitis, nephritis, sarcoid-like reaction, and pancreatic and adrenal atrophy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01935-2DOI Listing
February 2019

Multiple sclerosis outcomes after cancer immunotherapy.

Clin Transl Oncol 2019 Feb 20. Epub 2019 Feb 20.

Department of Internal Medicine, Medical Oncology, University of Kentucky, Lexington, USA.

Introduction: Neurological immune-related adverse events are a rare but potentially deadly complication after immune checkpoint inhibitor (ICI) treatment. As multiple sclerosis (MS) is an immune-mediated disease, it is unknown how ICI treatment may affect outcomes.

Methods: We analyzed the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database for pembrolizumab, atezolizumab, nivolumab, ipilimumab, avelumab, and durvalumab 2 years prior their FDA approval until December 31, 2017, to include all cases with confirmed diagnosis/relapse of MS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-019-02060-8DOI Listing
February 2019

Predictors of pneumonitis-free survival following lung stereotactic body radiation therapy.

Transl Lung Cancer Res 2019 Feb;8(1):15-23

Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.

Background: Radiation pneumonitis is a common toxicity following lung stereotactic body radiation therapy (SBRT). We explored whether motion management technique, in conjunction with patient and treatment characteristics, is a predictor of radiation pneumonitis-free survival (PNFS).

Methods: A single institution multi-center lung SBRT database was retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.10.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351398PMC
February 2019

Comprehensive clinical implications of homeobox A10 in 3,199 cases of non-small cell lung cancer tissue samples combining qRT-PCR, RNA sequencing and microarray data.

Am J Transl Res 2019 15;11(1):45-66. Epub 2019 Jan 15.

Department of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi, Zhuang Autonomous Region, People's Republic of China.

In the current study, we proposed to explore the potential role and related signaling pathways of Homobox A10 (HOXA10) in non-small cell lung cancer (NSCLC). HOXA10 levels in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) were detected by qRT-PCR and the expression of HOXA10 was significantly up-regulated in the NSCLC tissue of all 55 pairs (P = 0.037). Read More

View Article

Download full-text PDF

Source
January 2019

Expression profile and bioinformatics analysis of COMMD10 in BALB/C mice and human.

Cancer Gene Ther 2019 Feb 21. Epub 2019 Feb 21.

Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

COMMD10, a member of COMMD protein, has been proved to target p65 NF-kappaB (nuclear factor-kappaB) subunit and reduce its nuclear translocation, thereby leading to the inactivation of NF-kappaB pathway and suppression of colorectal cancer invasion and metastasis. The aim of this study is to explore its expression pattern and tissue distribution in human normal tissues and other tumor tissues and to investigate the relevant mechanism. We firstly provided the expression profile and histological distribution of COMMD10 in various BALB/c mice tissues and identified the biological distribution of COMMD10 in different kinds of human normal and tumor tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0087-9DOI Listing
February 2019

Association between Family History of Cancer and Lung Cancer Risk among Japanese Men and Women.

Tohoku J Exp Med 2019 ;247(2):99-110

Division of Community Health, Tohoku University Graduate School of Medicine.

Although cigarette smoking is a major risk factor for lung cancer, genetic susceptibility may also affect lung cancer risk. To explore the role of genetic risk, this case-control study investigated the association between family history of cancer at several sites and lung cancer risk. A total of 1,733 lung cancer cases and 6,643 controls were selected from patients aged 30 years and over admitted to a single hospital in Japan between 1997 and 2009. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1620/tjem.247.99DOI Listing
January 2019

Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.

Biomed Pharmacother 2019 Feb 18;112:108590. Epub 2019 Feb 18.

Department of Tumor Biomarker Development, California Cancer Institute, Sino-American Cancer Foundation, 4978 Santa Anita Ave., Temple City, CA, 91007, USA. Electronic address:

Background: Etoposide-induced gene 24 (EI24) is an induction target of TP53-mediated apoptosis in human cancer cells. The hypothesis of this study is that EI24 might be a prognostic biomarker of non-small cell lung carcinoma (NSCLC).

Material And Methods: Fourteen gene expression NSCLC datasets with follow-up information (a total of 2582 accessible cases) were collected from Asia, Europe and North America. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.01.051DOI Listing
February 2019

Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer.

Oncotarget 2019 Jan 25;10(8):810-824. Epub 2019 Jan 25.

Tumor Biology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Transforming growth factor beta (TGFβ) plays a key role in regulating epithelial-to-mesenchymal transition (EMT). A gene expression signature () associated with TGFβ-induced EMT activities was developed using human Non-Small Cell Lung Carcinoma (NSCLC) cells treated with TGFβ-1 and subjected to Affymetrix microarray analysis. The final 105-probeset signature covers 77 genes, and a NanoString assay utilized a subset of 60 of these genes (TGFβ-EMTN signature). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368226PMC
January 2019

Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions.

Expert Rev Endocrinol Metab 2012 Sep;7(5):541-554

f Massachusetts General Hospital, Boston, MA, USA.

Approximately 90% of thyroid cancers are differentiated (DTCs) and have papillary, follicular or Hürthle cell morphology. Although treatment with surgery and radioactive iodine (I-131; RAI), as appropriate, is associated with significant cure rates and survival benefits, clonal disease progression with development of refractoriness to RAI poses a major therapeutic challenge in about 15% of patients. Traditional chemotherapeutic agents are relatively ineffective and are associated with significant toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.12.36DOI Listing
September 2012

The Enigmatic Protein Kinase C-eta.

Authors:
Alakananda Basu

Cancers (Basel) 2019 Feb 13;11(2). Epub 2019 Feb 13.

Department of Microbiology, Immunology & Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.

Protein kinase C (PKC), a multi-gene family, plays critical roles in signal transduction and cell regulation. Protein kinase C-eta (PKCη) is a unique member of the PKC family since its regulation is distinct from other PKC isozymes. PKCη was shown to regulate cell proliferation, differentiation and cell death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020214DOI Listing
February 2019

Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis.

Thorac Cancer 2019 Feb 18. Epub 2019 Feb 18.

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: The role of thoracic radiation therapy (TRT) after chemotherapy (CHT) in extensive-stage small cell lung cancer (ES-SCLC) has not been well defined. We investigated whether intensity-modulated radiotherapy (IMRT) improves outcomes in ES-SCLC after CHT compared to CHT alone.

Methods: A total of 292 patients who reached a complete response (CR), partial response (PR), or stable disease (SD) after CHT were assigned into groups: CHT + TRT and CHT alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13001DOI Listing
February 2019

Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study.

Thorax 2019 Feb 18. Epub 2019 Feb 18.

Department of Oncology, University of Cambridge, Cambridge, UK.

Background: Lung cancer 5-year survival has doubled over 15 years. Although the risk of second primary cancer is recognised, quantification over time is lacking. We describe the incidence of second and higher order smoking-related primary cancers in lung cancer survivors, identifying high-incidence groups and how incidence changes over time from first diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/thoraxjnl-2018-212456DOI Listing
February 2019

Adenoid cystic carcinoma with high-grade transformation forming spindle cell component of the submandibular gland.

Auris Nasus Larynx 2019 Feb 15. Epub 2019 Feb 15.

Department of Pathology, Fukuoka University, School of Medicine, Japan.

Adenoid cystic carcinoma (AdCC) with high-grade transformation (AdCC-HGT) is rare, and AdCC-HGT with spindle cell component is particularly rare. The patient was a 65-year-old man with a 5 cm sized swelling of the right submandibular gland. Submandibular sialoadenectomy was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anl.2019.01.014DOI Listing
February 2019

A case of metastatic brain tumor mimicking an expanding thalamic hematoma.

Surg Neurol Int 2019 15;10. Epub 2019 Jan 15.

Department of Pathology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.

Background: Brain tumor are a major etiology of secondary intracranial hemorrhage (ICH) because ICH in patients with cancer often occurs from an intratumoral hemorrhage. However, it is sometimes difficult to detect a tumor when it is tiny and buried, especially during initial examination.

Case Description: A 65-year-old woman who was diagnosed with pulmonary small cell carcinoma 6 months previously developed sudden-onset consciousness disturbance and left hemiparesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sni.sni_318_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357533PMC
January 2019

Are there any theranostic biomarkers in small cell lung carcinoma?

J Thorac Dis 2019 Jan;11(Suppl 1):S102-S112

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, Padova, Italy.

Small cell lung cancer (SCLC), an aggressive lung tumour with a poor prognosis, has a high load of somatic mutations, mainly induced by tobacco carcinogens given the strong association with smoking. Advances in genomic, epigenetic and proteomic profiling have significantly improved our understanding of the molecular and cellular biology of SCLC. Given the high mutational burden of SCLC the immune microenvironment is another exciting area under investigation even if it seems to be quite distinct from that of other solid tumours. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.12.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353747PMC
January 2019

Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.

J Thorac Dis 2019 Jan;11(Suppl 1):S89-S101

PATTERN: Group of French Thoracic Pathologists for Innovation and Translational Research, Synergie Lyon Cancer Foundation, Lyrican, France.

Lung cancer is the leading cause of cancer death worldwide with low response rates to conventional chemotherapy. New promising therapies have emerged based on programmed cell death protein 1 (PD-1) immunity checkpoint inhibitors (ICI), including anti-PD-1, such as nivolumab and pembrolizumab, or programmed death ligand 1 (PD-L1) inhibitors, such as atezolizumab, durvalumab, and avelumab. The prescription of pembrolizumab has been approved by FDA and EMA for advanced stages non-small cell lung carcinoma (NSCLC), restricted for first-line setting to patients whose tumor presents ≥50% of PD-L1 positive tumor cells (TC), and ≥1% for second-line and beyond, leading to consider PD-L1 assay as a companion diagnostic tool for pembrolizumab. Read More

View Article

Download full-text PDF

Source
http://jtd.amegroups.com/article/view/26452/19783
Publisher Site
http://dx.doi.org/10.21037/jtd.2018.12.103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353738PMC
January 2019
1 Read

miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6.

Onco Targets Ther 2019 25;12:835-848. Epub 2019 Jan 25.

Department of Nursing, The Affiliated Hospital of Southwest Medical University, Sichuan, 646000, China,

Background: The purpose of this study is to explore the potential biological roles of miR-101-5p in the progression of non-small-cell lung carcinoma (NSCLC).

Methods: The levels of miR-101-5p and chemokine (C-X-C motif) ligand 6 (CXCL6) in NSCLC tissues and cells were detected using the quantitative real-time PCR (qRT-PCR) assay. Proliferation, colony formation, migration and invasion assays were conducted using miR-101-5p-transfected NSCLC cells in vitro. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/mirna-101-5p-inhibits-the-growth-a
Publisher Site
http://dx.doi.org/10.2147/OTT.S184235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355169PMC
January 2019
1 Read

[Expression of hUTP14a in non-small cell lung cancer].

Beijing Da Xue Xue Bao Yi Xue Ban 2019 Feb;51(1):145-150

Department of Cell Biology, Peking University School of Basic Medical Sciences, Beijing 100191, China.

Objective: Human U three protein 14a (hUTP14a) facilitates tumorigenesis through promoting p53 and Rb degradation as well as enhancing c-Myc oncogenic activity. Moreover, hUTP14a expression is up-regulated in human hepatocellular cancer and colorectal cancer tissues. In this study, the expression of hUTP14a in non-small cell lung cancer (NSCLC) tissues was evaluated by immunohistochemistry staining (IHC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19723/j.issn.1671-167X.2019.01.025DOI Listing
February 2019

HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.

Radiother Oncol 2019 Feb 17;131:27-34. Epub 2018 Dec 17.

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

Purpose: The prognosis of unresectable stage III non-small cell lung cancer (NSCLC) was poor even after concurrent chemoradiotherapy. There remains a great need to develop novel therapeutic agents in combination with CCRT to improve outcomes. This prospective study sought to evaluate the efficacy and toxicities of the addition of endostar, an anti-angiogenesis agent, to concurrent etoposide, cisplatin (EP) and radiotherapy for treatment of patients with NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2018.10.032DOI Listing
February 2019

Small Cell Lung Cancer with Pituitary Metastasis Presenting as Secondary Adrenal Insufficiency: A Case Report and Literature Review.

Am J Case Rep 2019 Feb 17;20:207-211. Epub 2019 Feb 17.

Department of Endocrinology, University of California San Francisco, San Francisco, CA, USA.

BACKGROUND Pituitary gland metastasis is rarely the initial presentation of metastatic cancer. Most cases of pituitary gland metastasis are asymptomatic with diabetes insipidus being the most common symptomatic presentation. It can rarely present with symptoms of hormone underproduction such as secondary adrenal insufficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.913388DOI Listing
February 2019
1 Read

A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen.

J Mol Diagn 2019 Feb 8. Epub 2019 Feb 8.

School of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia. Electronic address:

Multiple biomarkers are under evaluation to guide the use of immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC), including programed death ligand 1 (PD-L1) tumor cell staining. We have developed a new approach that accurately quantifies PD-L1 status and identifies multiple mutations by using a single bronchoscopy specimen. A novel molecular marker was identified to detect the presence of malignant cells in radial endobronchial ultrasound bronchial brushings from NSCLC (n = 15) and benign (n = 13) nodules by quantitative real-time RT-PCR (RT-qPCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2018.10.001DOI Listing
February 2019
1 Read

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Cancer Immunol Immunother 2019 Feb 15. Epub 2019 Feb 15.

CureVac AG, Tübingen, Germany.

CV9201 is an RNActive-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n = 7) or metastatic (n = 39) NSCLC and at least stable disease after first-line treatment received five intradermal CV9201 injections (400-1600 µg of mRNA). The primary objective of the trial was to assess safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02315-xDOI Listing
February 2019
1 Read

Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway.

Cancer Biol Med 2018 Nov;15(4):400-414

State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.

Objective: Small cell lung carcinoma (SCLC) is considered one of the most aggressive types of lung cancer due to its rapid growth and early metastasis. No tumor markers or therapeutic targets have been demonstrated to be specific or effective in SCLC to date. This study aims to evaluate the potential of Flotillin1 (Flot1) as a target of SCLC treatment. Read More

View Article

Download full-text PDF

Source
http://www.cancerbiomed.org/index.php/cocr/article/view/1300
Publisher Site
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0053DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372910PMC
November 2018
2 Reads

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.

J Cancer Res Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

General-, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Introduction: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.

Materials And Methods: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02850-1DOI Listing
February 2019
1 Read

Annexin 1-nuclear factor-κB-microRNA-26a regulatory pathway in the metastasis of non-small cell lung cancer.

Thorac Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Pathology, School of Basic Medical Science, Guangzhou Medical University, Xinzao, China.

Background: Annexin 1 (ANXA1) expression is associated with the malignant tumor phenotype, making it an attractive therapeutic target. However, little is known about the regulation of ANXA1 in non-small cell lung cancer (NSCLC).

Methods: We investigated the biological roles of ANXA1 in tumor growth, migration, and invasion, and explored the possibility of ANXA1 as a potential therapeutic target for the treatment of NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.12982DOI Listing
February 2019
1 Read

Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?

J Cancer Res Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Purpose: To evaluate the prognostic value of FDG PET/CT metabolic parameter compared to clinico-pathological risk factors in surgical margin-negative stage IA non-small cell lung cancer (NSCLC) patients.

Methods: 167 patients with consecutive FDG PET/CT scans from 2009 to 2015 performed for staging of NSCLC stage IA with plans for curative surgery were retrospectively reviewed. Maximum standardized uptake value (SUVmax) of primary tumor and mean SUV of liver were acquired from PET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02858-7DOI Listing
February 2019
1 Read

Thymic Carcinoma Associated with Cerebellar Degeneration.

Eur J Case Rep Intern Med 2018 21;5(3):000780. Epub 2018 Mar 21.

Department of Internal Medicine, Villarrobledo General Hospital, Villarrobledo, Albacete, Spain.

We present the case of a 57-year-old man with ataxia and clinical and radiological features of cerebellar degeneration. Computed tomography showed a mediastinal mass and the patient was diagnosed with thymic carcinoma. Paraneoplastic cerebellar degeneration is aninfrequent disorder and its association with thymic carcinoma very rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000780DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346953PMC
March 2018
1 Read

Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.

Virchows Arch 2019 Feb 12. Epub 2019 Feb 12.

Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.

AbstractSeveral researches have been carried over the last few decades to understand of how cancer evades the immune system and thus to identify therapies that could directly act on patient's immune system in the way of restore or induce a response to cancer. As a consequence, "cancer immunotherapy" is conquering predominantly the modern scenario of the fight against cancer. The recent clinical success of immune checkpoint inhibitors (ICIs) has created an entire new class of anti-cancer drugs and restored interest in the field of immuno-oncology, leading to regulatory approvals of several agents for the treatment of a variety of malignancies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00428-019-02538-4
Publisher Site
http://dx.doi.org/10.1007/s00428-019-02538-4DOI Listing
February 2019
2 Reads

Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study.

Strahlenther Onkol 2019 Feb 11. Epub 2019 Feb 11.

Radiation Immuno-Oncology, Center for Translational Cancer Research TUM (TranslaTUM), Einsteinstr. 25, 81675, Munich, Germany.

Background: Membrane heat shock protein 70 (mHsp70) is indicative of high-risk tumors and serves as a tumor-specific target for natural killer (NK) cells stimulated with Hsp70 peptide (TKD) and Interleukin(IL)-2. Radiochemotherapy (RCT), mHsp70-targeting NK cells, and programmed death(PD)-1 inhibition were combined to improve the efficacy of tumor-specific immune cells in a non-small cell lung carcinoma (NSCLC) patient.

Patient: Following simultaneous RCT (64. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00066-019-01434-9
Publisher Site
http://dx.doi.org/10.1007/s00066-019-01434-9DOI Listing
February 2019
2 Reads

Evaluation of lobar lymph node metastasis in non-small cell lung carcinoma using modified total lesion glycolysis.

J Thorac Dis 2018 Dec;10(12):6932-6941

Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.

Background: Volumetric parameters based on 3-dimensional reconstruction have recently been introduced for cancer staging. We aimed to improve the ability to diagnose hilar lymph node metastasis in patients with non-small cell lung cancer.

Methods: We evaluated 142 patients with non-small cell lung cancer who underwent right upper lobectomy and radical lymph node dissection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.11.40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344716PMC
December 2018
1 Read

Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor.

J Thorac Dis 2018 Dec;10(12):6912-6920

Second Department of Surgery, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan.

Background: Pulmonary neuroendocrine tumor (NET) occurs with 20% of all lung cancers, and there are a limited number of literatures about the molecular aberrations, treatment and prognosis; especially in resected cases, as the operation indication for large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) is rare due to their aggressive behaviors. We investigated the relationship between postoperative survival and molecular expression patterns of pulmonary NET to establish a more effective treatment strategy.

Methods: In the present study, the curative surgical resection of pulmonary NET was reviewed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.11.115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344740PMC
December 2018
1 Read

Occult stage IIIA-N2 patients have excellent overall survival with initial surgery.

J Thorac Dis 2018 Dec;10(12):6670-6676

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Background: Patients may be found to have stage IIIA-N2 at the final pathology after the initial surgery. We want to determine the survival rate in this unique group of patients.

Methods: We reviewed all patients who underwent surgical resection for lung cancer from 2000 to 2011 who had pathologic stage N2 without induction therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.10.94DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344762PMC
December 2018
1 Read

Loss of stretch-activated channels, PIEZOs, accelerates non-small cell lung cancer progression and cell migration.

Biosci Rep 2019 Feb 11. Epub 2019 Feb 11.

Jilin Province Cancer Hospital, changchun, China

PIEZO channels involve in wound sealing, cell  proliferation in many cell types. Recent study in lung cancer by using next generation sequencing analysis has indicated that PIEZOs' functions were implicated in LC development. However, the expression and role of PIEZO channels in non-small cell lung cancer (NSCLC) progression remain elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BSR20181679DOI Listing
February 2019
1 Read

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

Lancet Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.

Background: Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor.

Methods: InnovaTV 201 is a phase 1-2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30859-3DOI Listing
February 2019
2 Reads

Acromegaly associated with GIST, non-small cell lung cancer, clear cell renal cancer, myeloma multiplex, medulla oblongata tumor, adrenal adenoma and follicular thyroid nodules.

Endokrynol Pol 2019 Feb 11. Epub 2019 Feb 11.

Dept. of Endocrinology, Diabetes and Isotope Therapy, Medical University Wroclaw, Pasteura 4, 50-367 Wrocłąw, Poland.

Background: Acromegaly is associated with increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion which may support tumor development and growth.

Case Presentation: A 68-year old woman was diagnosed with acromegaly due to typical clinical and hormonal characteristics. While a contrast-enhanced MRI at diagnosis did not reveal a pituitary adenoma, a 5 mm lesion was identified on repeat scanning 13 months later. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/EP.a2019.0005DOI Listing
February 2019
5 Reads

Nr5a2 promotes cancer stem cell properties and tumorigenesis in nonsmall cell lung cancer by regulating Nanog.

Cancer Med 2019 Feb 10. Epub 2019 Feb 10.

Laboratory of Translational Cancer Stem Cell Research, Institute of Life Sciences, Chongqing Medical University, Chongqing, China.

Lung cancer has the highest mortality rate due to late diagnosis and high incidence of metastasis. Cancer stem cells (CSCs) are a subgroup of cancer cells with self-renewal capability similar to that of normal stem cells (NSCs). While CSCs may play an important role in cancer progression, mechanisms underlying CSC self-renewal and the relationship between self-renewal of the NSCs and CSCs remain elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1992DOI Listing
February 2019
1 Read

Serum Interleukin-27 Level in Different Clinical Stages of Lung Cancer.

Open Access Maced J Med Sci 2019 Jan 5;7(1):45-49. Epub 2019 Jan 5.

Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background: Advanced lung cancer is indicated with rapid disease development. Interleukin 27 (IL-27) is regarded as a cytokine with anti-tumour activities.

Aim: Since, the impact of type of lung cancer on the level of IL-27 in patient's serum has not yet been investigated; current study evaluated the clinical stages according to American Joint Committee on Cancer (AJCC) criteria, Tumor-Node-Metastasis (TNM) stage and the lung cancer spread (localized or widespread) and it's correlation with serum IL-27. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352477PMC
January 2019
1 Read

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Eur J Cancer 2019 Feb 7;109:183-191. Epub 2019 Feb 7.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou 510080, People's Republic of China. Electronic address:

Background: Nab-paclitaxel/carboplatin (nab-PC) and gemcitabine/carboplatin (GC) are the standard first-line chemotherapy in non-small cell lung carcinoma. Up to now, there is no head to head trial to compare nab-PC with GC in advanced squamous cell lung carcinoma.

Patients And Methods: A multicentre randomised phase II trial was performed to compare the efficacy and safety for nab-PC with GC in previously untreated patients with advanced squamous cell lung carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.01.007DOI Listing
February 2019
1 Read
5.417 Impact Factor

FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.

EBioMedicine 2019 Feb 6. Epub 2019 Feb 6.

Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan 450001, China. Electronic address:

Background: The resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKI) is a major challenge in the treatment of non-small cell lung cancer (NSCLC). Understanding the molecular mechanisms behind resistance is therefore an important issue. Here we assessed the role of EGFR pathway substrate 8 (EPS8) and Forkhead box O 3a (FoxO3a) as potentially valuable targets in the resistance of NSCLC . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.01.053DOI Listing
February 2019
3 Reads

Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach.

AAPS J 2019 Feb 8;21(2):27. Epub 2019 Feb 8.

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, 455 Kapoor Hall, Buffalo, New York, 14214, USA.

Tumor doubling time can significantly affect the outcome of anticancer therapy, but it is very challenging to determine. Here, we present a statistical approach that extracts doubling times from progression-free survival (PFS) plots, which inherently contains information regarding the growth of solid tumors. Twelve cancers were investigated and multiple PFS plots were evaluated for each type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-019-0302-5DOI Listing
February 2019
1 Read

Surgical resection of small cell lung carcinoma: prognostic factors and the tumor microenvironment.

J Thorac Oncol 2019 Feb 5. Epub 2019 Feb 5.

Georgetown University, Washington DC, U.S.A. Electronic address:

Background: Surgery in small cell lung cancer (SCLC) is limited to very early stages, but several reports suggest a potential broader role. Little is known of the influence of microenvironment on the biology of SCLC.

Methods: We assessed the clinical prognostic factors in a large series of resected SCLC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.019DOI Listing
February 2019
1 Read

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis.

Thorac Cancer 2019 Feb 7. Epub 2019 Feb 7.

Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China.

Background: The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC.

Methods: Data of patients diagnosed with LCNEC and ONSCLC from 2004 to 2014 were obtained from the Surveillance, Epidemiology, and End Results dataset. Pearson's chi-square tests were used to compare differences in clinicopathological characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.12993DOI Listing
February 2019
1 Read

Recent Advances in Pathology: The 2019 Annual Review Issue of the Journal of Pathology.

J Pathol 2019 Feb 8. Epub 2019 Feb 8.

RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

In this Annual Review Issue of The Journal of Pathology, we present 15 invited reviews on topical aspects of pathology, ranging from the impacts of the microbiome in human disease through mechanisms of cell death and autophagy to recent advances in immunity and the uses of genomics for understanding, classifying and treating human cancers. Each of the reviews is authored by experts in their fields and our intention is to provide comprehensive updates in specific areas of pathology in which there has been considerable recent progress. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/path.5255
Publisher Site
http://dx.doi.org/10.1002/path.5255DOI Listing
February 2019
6 Reads

Management of brain metastases from large cell neuroendocrine carcinoma of the lung: improved outcomes with radiosurgery.

Acta Oncol 2019 Feb 7:1-6. Epub 2019 Feb 7.

a Division of Radiation Oncology , Allegheny Health Network Cancer Institute , Pittsburgh , PA , USA.

Objectives: Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare pulmonary tumor, having similar natural history and management strategy as small cell lung cancer. Therefore, the management of brain metastases in these patients has mirrored that of SCLC through the use of whole brain radiation therapy (WBRT). We used the National Cancer Database (NCDB) to look at predictors of stereotactic radiosurgery (SRS) and any potential differences in outcomes for patients with brain metastases from LCNEC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2018.1564841DOI Listing
February 2019
1 Read

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

Eur J Cancer 2019 Feb 4;109:154-161. Epub 2019 Feb 4.

Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Introduction: Durvalumab selectively blocks programmed cell death ligand-1 (PD-L1) binding to programmed cell death-1. Encouraging clinical activity and manageable safety were reported in urothelial carcinoma, non-small-cell lung cancer (NSCLC), hepatocellular carcinoma (HC) and small-cell lung cancer (SCLC) in a multicenter phase I/II study. Safety and clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) were evaluated in the expansion phase. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.12.029DOI Listing
February 2019
5 Reads

NF-κB-Induced Upregulation of miR-548as-3p Increases Invasion of NSCLC by Targeting PTEN.

Anticancer Agents Med Chem 2019 Feb 6. Epub 2019 Feb 6.

Department of Medical Genetics, Faculty of Medicine, cILTAM Cancer Biology Laboratory, Pamukkale University, Kinikli, Denizli. Turkey.

Background: Non-Small Cell Lung Cancer (NSCLC) is an aggressive cancer type due to high metastatic capacity. Nuclear Factor Kappa B (NF-κB) is a consistently active transcription factor in malignant lung cancer cells and has crucial significance in NSCLC progression. It is also implicated in the transcriptional regulation of many genes including microRNAs (miRNAs) that function as tumor suppressor or oncogene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871520619666190206165215DOI Listing
February 2019
4 Reads